http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
송용중(Yong Jung Song),윤병선(Byoung Sun Yoon),김현희(Hyun Hee Kim),안준태(Joon Tae Ahn),최석철(Suck Chul Choi),유상영(Sang Young Ryu),김종훈(Jong Hoon Kim),김병기(Byoung Gie Kim),박상윤(Sang Yoon Park),이경희(Kyung Hee Lee) 대한산부인과학회 2001 Obstetrics & Gynecology Science Vol.44 No.12
N/A Objectives : This study is to investigate clinicopathologic characteristics, survival and prognostic factors in patients with Krukenberg tumor of the ovary. Material & Methods : From Jan. 1991 to Dec. 2000, 42 patients with Krukenberg tumor of the ovary were investigated with clinical profiles, such as age, stage, primary sites, clinical symptoms, and survival, retrospectively. Results : A mean age of 42 patients was 44.8 years (range 27-77). Stomach was the most frequent primary site (30/42, 71.4%), followed by colon (7/42, 16.7%) and gallbladder (1/42, 2.4%). In 38 patients, primary sites diagnosed before or after 1 month of diagnosis of Krukenberg tumor of ovary (36/38 cases, 94.7%). The most common feature of patients with Krukenberg tumor of ovary was bilateral abdominal mass. 5-year survival rate of patients with Krukenberg tumor of ovary was 8.94% (95% CI=3.33-14.55) and median survival time was 11 months. Age, bilaterality of tumor, time of diagnosis, presence of ascites and the primary site did not affect the survival. The patients who received post-operative adjuvant chemotherapy had better 3-year survival than those who did not (17.28% vs 10% p=0.03). Conclusion : Krukenberg tumor of the ovary is an aggressive tumor with poor prognosis. Post-operative adjuvant chemotherapy may increase the survival of patients with Krukenberg tumor of the ovary. Further prospective studies for the role of surgery and chemotherapy are needed.
A prospective study of examination under anesthesia(EUA) for patients with cervical cancer (초)
송용중 ( Yong Jung Song ),( Jong Ha Hwang ),( Sae Hyun Park ),( Myong Cheol Lim ),( Dae Cheol Jung ),( Sang Soo Seo ),( Sok Bom Kang ),( Joo Young Kim ),( Sang Yoon Park ) 대한산부인과학회 2010 대한산부인과학회 학술대회 Vol.96 No.-
나용진 ( Yong Jin Na ),송용중 ( Yong Jung Song ),구윤희 ( Yun Hee Koo ) 대한폐경학회 2012 대한폐경학회지 Vol.18 No.3
호르몬 치료의 궁극적인 결과로서 사망률의 감소에 관하여 현재까지 많은 논란이 있다. 대규모 전향적 코호트 연구에서는 교란 변수들을 보정한 이후에도 호르몬 치료를 시행한 경우가 시행하지 않은 경우에 비해 전체 사망률을 의미 있게 감소시켰다. WHI 연구결과의 두 번째 분석 (second analysis)에서는 호르몬 치료군에서 30%의 사망률 감소를 보고하였고, 과거의 관찰연구들도 이와 유사한 결과를 보여주었다. WHI 연구결과의 두 번째 분석을 포함한 메타분석에서는 젊은 폐경여성에서의 호르몬 치료는 사망률을 감소시키는 것으로 나타났다. 비록 득과 실에 대한 이해에 있어 엄청난 동요가 있어 왔지만 적어도 젊은 폐경여성에서의 호르몬 치료는 심혈관질환의 이환율 및 사망률을 줄이고 나아가 전체 사망률을 줄일 수 있을 것으로 생각된다. There was controversy about decrease in mortality as the eventual result of hormone replacement therapy (HRT). The reduction of mortality was known in large observational-cohort studies in women with HRT compared with non-HRT after correction of confounding factors. The second analysis of Women`s Health Initiative (WHI) results revealed that the 30% decrease in mortality was observed in HRT users. These findings resemble with the results of past observational studies. The meta-analysis including the second analysis of WHI results showed that HRT use in young menopausal women decrease the mortality. Although there was a chaos about the risk and benefit of HRT since the first announcement of WHI study in 2002, HRT in young menopausal women could decrease the morbidity and mortality related to coronary heart disease and stroke. (J Korean Soc Menopause 2012;18: 133-138)
상피성 난소암에서 수술후 일차 항암화학요법으로 시행된 Paclitaxel - Cisplatin 의 효용성에 대한 연구
김상희(Sang Hee Kim),송용중(Yong Jung Song),이향(Hyang Lee),이삼미(Sam Mi Lee),최석철(Suck Chul Choi),유상영(Sang Young Ryu),김병기(Byoung Gie Kim),박상윤(Sang Yoon Park),이경희(Kyung Hee Lee) 대한산부인과학회 2001 Obstetrics & Gynecology Science Vol.44 No.12
N/A Objective : The purpose of this retrospective study is to assess the efficacy and toxicity of paclitaxel/cisplatin as first-line chemotherapy after cytoreductive surgery in patients with epithelial ovarian cancer. Material & Methods : From November 1999 to April 2001, 31 patients with histologically-proven epithelial ovarian cancer not previously treated with chemotherapy entered the study. FIGO stage IA or IB and grade 1 or 2 tumors were excluded. A comprehensive staging was performed during initial laparotomy. Paclitaxel was administered at a dose of 135 mg/m2, intravenously with cisplatin (75 mg/m2) every 3 weeks for 6 planned cycles, with prophylactic oral dexamethasone regimen (20 mg b.I.d.). The response of patients was evaluated with tumor markers and CT before and after chemotherapy. Responses and toxicities were defined according to the Gynecologic Oncology Group (GOG) criteria. Results : The overall response rates were 73% (16/22) in patients with residual disease after cytoreductive surgery (complete response, 64%; partial response, 9%). The median survival was 18 months. Grade 3/4 neutropenia and neuropathy (grade 2) were observed in 16 (52%), 12 (39%) patients, respectively. Conclusion : The combination of paclitaxel and cisplatin is a well tolerated regimen with significant activity in the treatment of epithelial ovarian carcinoma after surgery.
김상희(Sang Hee Kim),김현희(Hyun Hee Kim),송용중(Yong Jung Song),윤병선(Byung Sun Yoon),최석철(Suck Chul Choi),유상영(Sang Young Ryu),이경희(Kyung Hee Lee) 대한산부인과학회 2002 Obstetrics & Gynecology Science Vol.45 No.1
It is estimated that approximately 35% of patients with invasive cervical cancer will have recurrent or persistent disease following therapy. The common metastatic sites of recurrent cervical cancer included the lung, liver and vertebra, however, colon metastases from cervical cancer were extremely rare. Recently we experienced a case of colonic metastasis in a patient with cervical cancer who had been treated with radiation and chemotherapy. We present this case with a brief review of literature.
우희정 ( Hee Joung Woo ),김상헌 ( Sang Heon Kim ),김기동 ( Ki Dong Kim ),박상일 ( Sang Il Park ),송용중 ( Yong Jung Song ),김법종 ( Beob Jong Kim ),김문홍 ( Moon Hong Kim ),최석철 ( Seok Cheol Choi ),유상영 ( Sang Young Ryu ),이 대한산부인과학회 2009 Obstetrics & Gynecology Science Vol.52 No.2
목적: 원발성 복막 암종으로 진단받은 21명의 환자들을 대상으로 임상조직학적 특징과 예후인자를 알아보고자 하였다. 연구 방법: 1996년 1월부터 2005년 12월까지 본원에서 수술을 받고, 원발성 복막 암종으로 진단받은 21명의 환자들의 의무기록을 후향적으로 검토하여 임상조직학적 특징을 조사하였다. 예후인자를 찾기 위하여 임상조직학적 변수들과 수술 후 보강화학요법에 대한 치료반응, 무진행생존기간, 전체생존기간과의 연관성을 단변랑, 다변량 분석을 이용하여 평가하였다. 결과: 모든 환자들이 3기 이상의 진행된 암종을 가지고 있었고, 잔류종양의 크기가 1 cm 미만인 환자는 12명, 1 cm 이상인 환자는 9명이었다. 수술 후 보강화학요법에 대한 반응률은 47.6%였다. 무진행생존기간 중간값은 8개월 (범위 1~95)이었고, 전체 생존기간 중간값은 14개월 (범위 1~95)이었다. 병기, 보강화학요법에 대한 치료반응, 신보강화학요법 시행 여부는 무진행생존기간과 연관성이 있었고, 병기와 보강화학요법에 대한 치료반응은 전체생존기간과도 연관성을 보였다. 그러나, 다변량 분석상 모든 변수가 무진행생존기간이나 전체생존기간과 유의한 상관관계를 보이지 않았다. 결론: 원발성 복막 암종 환자는 종양감축술과 보강화학요법을 시행받았음에도 대부분 좋지 않은 예후를 보였다. 본 연구에서는 원발성 복막 암종의 예후인자를 확인할 수 없었다. Objective: The objective of this study was to examine the clinicopathologic characteristics and prognostic factors of primary peritoneal carcinoma (PPC). Methods: Clinicopathologic variables were obtained by examining the medical records of patients with PPC who were diagnosed and treated at our institute, between January 1996 and December 2005. To find prognostic factors, the association of clinicopathologic variables with survival was evaluated by univariate and multivariate analysis. Results: All patients had advanced-stage tumors. Residual tumor was smaller than 1 cm in 12 patients and was equal or larger than 1 cm in nine patients. The response rate to adjuvant chemotherapy was 47.6%. The median progression-free survival was eight months (range 1~95) and the median overall survival was 14 months (range 1~99). In univariate analysis, stage, the response to adjuvant chemotherapy, and neoadjuvant chemotherapy were associated with survival. However, in multivariate analysis, no variables were associated with survival. Conclusion: In spite of aggressive treatments, patients with PPC had poor prognosis. No prognostic factors were identified in this study.